Journal Article

GLIOMAS GENETIC MARKERS AND PREFERENTIAL SUPRATENTORIAL BRAIN LOCATIONS

Isaac Phang, Anna Craig-Mcquaide, Adamantios Mavrakis and Athanasios Grivas

in Neuro-Oncology

Volume 20, issue suppl_5, pages v349-v349
Published in print October 2018 | ISSN: 1522-8517
Published online October 2018 | e-ISSN: 1523-5866 | DOI: https://dx.doi.org/10.1093/neuonc/noy129.022
GLIOMAS GENETIC MARKERS AND PREFERENTIAL SUPRATENTORIAL BRAIN LOCATIONS

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Neurology

GO

Show Summary Details

Preview

Abstract

INTRODUCTION

Gliomas are associated with preferential locations in secondary functional areas. We examine our data to see if there is a genetic difference between the gliomas in different supratentorial locations using IDH-1, MGMT methylation and 1p19q co-deletion status. Methods WHO Grade II and III glioma patients with histology were included retrospectively from the MDT database from 2013 – 2017. Glioma location was determined by the MRI report. In cases where the glioma expanded beyond one lobe, consensus was obtained between the authors to determine where the majority of the tumour bulk was located. IDH-1, MGMT methylation and 1p19q co-deletion status were obtained from the histopathology report. χ2test with Bonferroni correction was used to compare the actual and expected numbers observed. Results191 gliomas were included. There were 55 astrocytomas Grade II, 81 astrocytomas Grade III, 24 oligodendrogliomas Grade II, 29 oligodendrogliomas Grade III and 2 anaplastic pleomorphic xanthoastrocytomas. There were 74 frontal, 25 insular, 64 temporal, 20 parietal and 8 basal ganglia tumours. 64.1% of the gliomas were IDH-1 mutated. However, 82.4% in the frontal lobe, 70.8% in the insula, 46.2% in the temporal lobe, 60.0% in the parietal lobe and 14.3% in the basal ganglia regions were IDH-1 mutated (p< 0.001). 57.3% of the gliomas were MGMT methylated. However, 64.9% in the frontal lobe, 62.5% in the insula, 50.8% in the temporal lobe, 60.0% in the parietal lobe and 42.9% in the basal ganglia regions were MGMT methylated (p<0.001). 31.3% of the gliomas were 1p19q co-deleted. However, 43.2% in the frontal lobe, 29.2% in the insula, 23.1% in the temporal lobe, 25% in the parietal lobe and none in the basal ganglia were 1p19q co-deleted (p<0.001).

CONCLUSION

Our data suggest gliomas in different supratentorial locations have genetic differences based on the three genetic markers.

Journal Article.  0 words. 

Subjects: Medical Oncology ; Neurology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.